Person—timing of glycoprotein IIb/IIIa inhibitor prescription, code N

Exported from METEOR (AIHW's Metadata Online Registry)

Person—timing of glycoprotein IIb/IIIa inhibitor prescription, code N

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Timing of glycoprotein IIb/IIIa inhibitor prescription
METEOR identifier:	349367
Registration status:	Health!, Standard 01/10/2008
Definition:	The timing of care when a glycoprotein IIb/IIIa inhibitor is prescribed to a person, as represented by a code.
Data Element Concept:	Person—timing of glycoprotein IIb/IIIa inhibitor prescription
Value Domain:	Timing of glycoproteinIIb/IIIa inhibitor prescription code N[N]

Value domain attributes

Representational attributes

Representation class:	Code
Data type:	Number
Format:	N
Maximum character length:	1

	Value	Meaning
Permissible values:	1	Initial medical management: preceding invasive management
	2	During invasive management
	3	Following invasive management
Supplementary values:	9	Not stated/inadequately described

Data element attributes

Collection and usage attributes

Guide for use:	Invasive management includes angiography, percutaneous coronary intervention and coronary artery bypass graft.
	CODE 1 Initial medical management: preceding invasive management
	Use this code when a glycoprotein IIb/IIIa inhibitor is prescribed before invasive management is to be performed.
	CODE 2 During invasive management
	Use this code when a glycoprotein IIb/IIIa inhibitor is prescribed while invasive management is being performed.
	CODE 3 Following invasive management
	Use this code when a glycoprotein IIb/IIIa inhibitor is prescribed after invasive management has been performed.
Collection methods:	Record each time a glycoprotein IIb/IIIa inhibitor is prescribed for a person.

Relational attributes

Implementation in Data Set Specifications: [Acute coronary syndrome pharmacotherapy data cluster](#)
[Health!,](#) Standard 01/10/2008
Conditional obligation: If prescribed, provide a phase for each time glycoprotein IIb/IIIa inhibitor therapy is prescribed.